Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rezivertinib in EGFR Mutation Advanced or Recurrent NSCLC
NCT03386955Phase 2Completed
- Sponsor
- Beta Pharma
- Start
- Aug 2017
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rezivertinib in non-small cell lung cancer (NSCLC), sponsored by Beta Pharma. Started Aug 2017; status: completed.
02
Drugs
rezivertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03386955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03386955.